Pure Global
NCT06339788

Pharmacokinetics of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers

A Randomized, Open-label, Crossover, Phase 1 Study to Evaluate Pharmacokinetics and Safety of HD-P023 in Comparison With Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers
Handok Inc.·Phase 1·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Healthy Volunteers
Drug/Device/Intervention
HD-P023
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Handok Inc.
Timeline & enrollment
Phase
Phase 1
Start date
Apr 01, 2024
End date
Nov 01, 2024
Enrollment
40 participants
Primary outcome

Area under the plasma concentration versus time curve (AUCt) of Teneligliptin and Empagliflozin,Peak Plasma Concentration (Cmax) of Teneligliptin and Empagliflozin

Summary

The purpose of this study is to compare the pharmacokinetics and safety of HD-P023 and
 coadministration of Teneligliptin and Empagliflozin in healthy adult volunteers

ICD-10 classifications
Healthy person accompanying sick personRoutine general health check-up of armed forcesRoutine general health check-up of sports teamsRoutine general health check-up of inhabitants of institutions
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06339788
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06339788 through Pure Global AI's free database. This Phase 1 trial is sponsored by Handok Inc. and is currently Not yet recruiting. The study focuses on Healthy Volunteers. Target enrollment is 40 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.